Nicole Balmaceda MD (She/Her)

PubMed

• Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma.
  Hiroyuki Ishida, Salvador Rodriguez Franco, Oskar Franklin, Yuki Fujiwara, Andrii Khomiak
  Annals of Surgical Oncology. 2026-03-01
• Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model.
  Robert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, John J Arcaroli, Stacey M Bagby
  Frontiers in Oncology. 2026-01-01
• Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.
  Robert W Lentz, Julie Lang, Todd M Pitts, Patrick Blatchford, Junxiao Hu
  Cancer Research Communications. 2025-11-01

Journal Articles

• Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer  
  Robert Lentz, Junxiao Hu, Hannah Robinson, Nicole Balmaceda, Christopher Lieu, Journal of the National Comprehensive Cancer Center, 8/1/2025
• Oligometastatic Pancreatic cancer: current state of management and emerging therapies  
  Nicole Balmaceda, The Oncologist, 6/19/2025
• State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care  
  Nicole Balmaceda, American Society of Clinical Oncology Educational Book, 5/21/2024

Abstracts/Posters

• The association of antibiotic use and survival among patients receiving first line immunotherapy-based treatment for advanced gastroesophageal cancers
  Nicole Balmaceda, Sunnie Kim, Journal of Clinical Oncology, ASCO GI, 1/23/2025
• Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.
  Aleksander Lech Chojecki, Danielle Boselli, Allison Dortilus, Issam Hamadeh, Stephanie Begley, Tommy Chen, Rupali Bose, Nikolai Alexandrovich Podoltsev, Amer Methqal Z..., Journal of Clinical Oncology , 2023 ASCO, 6/1/2023